Three-Month Period Ended | Nine-Month Period Ended | |||||||||||||||||||
December 25,
2020 |
September 25,
2020 |
December 27,
2019 |
December 25,
2020 |
December 27,
2019 | ||||||||||||||||
(Dollars in thousands) | ||||||||||||||||||||
Reconciliation of Operating Expenses | ||||||||||||||||||||
GAAP Operating Expenses | $ | 98,649 | $ | 49,368 | $ | 50,394 | $ | 199,186 | $ | 155,595 | ||||||||||
Research and Development Expenses | ||||||||||||||||||||
GAAP Research and Development Expenses | 30,999 | 25,130 | 25,485 | 80,509 | 77,565 | |||||||||||||||
Stock-based compensation | 2,984 | 32 | 20 | 3,037 | 65 | |||||||||||||||
AMTC Facility consolidation one-time costs | 1 | — | — | 2 | — | |||||||||||||||
COVID-19 related expenses | 32 | — | — | 92 | — | |||||||||||||||
Transaction fees | — | — | — | 18 | — | |||||||||||||||
Non-GAAP Research and Development Expenses | 27,982 | 25,098 | 25,465 | 77,360 | 77,500 | |||||||||||||||
Selling, General and Administrative Expenses | ||||||||||||||||||||
GAAP Selling, General and Administrative Expenses | 67,650 | 24,238 | 24,909 | 118,677 | 78,030 | |||||||||||||||
Stock-based compensation | 38,198 | 495 | 236 | 39,020 | 849 | |||||||||||||||
AMTC Facility consolidation one-time costs | 1,620 | 1,358 | — | 4,138 | — | |||||||||||||||
Amortization of acquisition-related intangible assets | 71 | 9 | — | 80 | — | |||||||||||||||
COVID-19 related expenses | 338 | 398 | — | 4,676 | — | |||||||||||||||
Transaction fees | 1,729 | 1,871 | 2,335 | 3,699 | 3,782 | |||||||||||||||
Severance | (181 | ) | — | 454 | 156 | 3,152 | ||||||||||||||
Non-GAAP Selling, General and Administrative Expenses | 25,875 | 20,107 | 21,884 | 66,908 | 70,247 | |||||||||||||||
Total Non-GAAP Adjustments | 44,792 | 4,163 | 3,045 | 54,918 | 7,848 | |||||||||||||||
Non-GAAP operating expenses * | $ | 53,857 | $ | 45,205 | $ | 47,349 | $ | 144,268 | $ | 147,747 | ||||||||||